ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options
Jean‐Jacques Kiladjian(Délégation Paris 5), Christoph Klade(Intercell (Austria)), Francisca Ferrer‐Marín(Centre for Biomedical Network Research on Rare Diseases), Steffen Koschmieder(RWTH Aachen University), Martin Grießhammer(Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie), Chloé James(Université de Bordeaux), Árpád Illés(University of Debrecen), Paola Guglielmelli(Azienda Ospedaliero-Universitaria Careggi), Kurt Krejcy(AOP Orphan (Austria)), Andreas Reiter(Heidelberg University), Stefanie Schlager(Hewlett-Packard (Austria)), Martin Unger, Eloise Beggiato, Tomasz Sacha, O Cerná, Valentín García‐Gutiérrez(Universidad de Alcalá), Evangelos Terpos(National and Kapodistrian University of Athens), M. Lazaroiu, Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz), Haifa Kathrin Al‐Ali(University Hospital in Halle), Konstanze Döhner(University Hospital Ulm), Valerio De Stefano(Agostino Gemelli University Polyclinic), Jiřı́ Mayer(Masaryk University), Maria Bieniaszewska(Gdańsk Medical University), Sebastian Grosicki(Medical University of Silesia), Joanna Góra‐Tybor, Albert Wölfler(Medical University of Graz), Blanca Xicoy Cirici(Universitat Autònoma de Barcelona), Maria‐Theresa Krauth(Medical University of Vienna), Victoria Empson(AOP Orphan (Austria)), Ciprian Tomuleasa(Iuliu Hațieganu University of Medicine and Pharmacy), Massimo Breccia(Policlinico Umberto I), Florian H. Heidel(Medizinische Hochschule Hannover), Stefan Schmidt(Innsbruck Medical University), Ana-Manuela Crisan(Institutul Clinic Fundeni), Zsolt György Nagy(Semmelweis University), Franck‐Emmanuel Nicolini(Centre Léon Bérard), Catalin Doru DANAILA(Institutul Regional de Oncologie), Alberto Álvarez‐Larrán(Hospital Clínic de Barcelona), Vassiliki Pappa(University General Hospital Attikon), Francesca Palandri(Istituto Oncologico Romagnolo)
Cited by 14
Related Papers
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k